Immuno-Oncology Drugs Market by Immunotherapy Type (Immune checkpoint inhibitors, Monoclonal antibody-based drugs Adaptive cell transfer therapy, Anti-body drug conjugate based-therapy, Cytokine-based therapy, and Vaccine-based immunotherapy), by Cancer Type (Lung cancer, Melanoma, Bladder Cancer, Head and Neck Cancer, Leukemia, Lymphoma, Multiple Myeloma, Renal Cancer, and Others), by Distribution Channel (Hospital Pharmacy and Retail Pharmacy), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2017 - 2025

Immuno oncology is a type of cancer therapy designed to strengthen the body’s immune system to fight the cancer. These immunotherapies such as immune checkpoint inhibitor or cell transfer therapyimprove immune response of the patient against cancerous cells. Immunotherapies either act against immune checkpoint produced by cancer cells that reduces the intensity of immune responses towards them or stimulate the activities of specific components of the immune system. Immune checkpoint inhibitors is the most widely used therapy.

Increasing prevalence of cancer to fuel growth of immuno-oncology drugs market

According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, 8.8 million deaths, and 32.6 million people living with cancer worldwide. Immuno-oncology therapy is effective for treatment of cancers such as melanoma, bladder cancer, head and neck cancer, leukemia, lung, multiple myeloma, lymphoma, and renal cancer. Furthermore, immuno-oncology has less side effect than chemotherapy, radiation therapy, and surgery. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy offered by Juno Therapeutics, Inc and Kite Pharma. Immuno-oncology drugs has proven clinical profile and increasing approvals to include more indicationfor existing drugs such as nivolumab is in turn expected to boost growth of the immuno-oncology drugs market.

However, high costs associated with therapy is restraining growth of the immuno-oncology drugs market. Immuno oncology drugs prescribed with chemotherapy increases the cancer treatment cost. According to Immuno-Oncology Summit Europe 2017, combination of immunotherapy with chemotherapy and targeted therapy improves survival rate of cancer patient. In 2017, Merck & Company received approval for immune checkpoint inhibitor brand Keytruda (pembrolizumab) for its use in combination with other anti-cancer drugs such as pemetrexed and carboplatin in non-squamous non-small cell lung cancer.

Immuno-oncology drugs market taxonomy:

On the basis of immunotherapy type:  

  • Immune checkpoint inhibitors
  • Monoclonal antibody based drugs
  • Adoptive cell transfer therapy (CAR-T Cell therapy ,TCR Therapy, TIL Therapy)
  • Anti-body drug conjugates
  • Cytokine based immunotherapy
  • Vaccines

On the basis of cancer type:

  • Lung cancer
  • Melanoma
  • Bladder cancer
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Head and neck cancer
  • Others

On the basis of distribution channel:

  • Hospital Pharmacy
  • Retail Pharmacy

U.S. to dominate the immuno-oncology drugs market, owing to high prevalence of cancer

The U.S. has a robust healthcare infrastructure and is characterized by high availability of novel anti-cancer therapy options. According to a report published in American Cancer Society’s Cancer Journal for Clinicians, around 1,735,350 new cancer cases are estimated to be diagnosed in 2018 in U.S., including around 87,290 cases of melanoma, for which drugs such as ipilimumab (Brand-Yeroy) and pembrolimumab (Brand-Keytruda) have been approved. Furthermore, expansion of indications for already approved drug would open up new opportunities for immuno-oncology market. Currently, atezolizumab (Brand-Tecentriq) is indicated for type of cancers such as melanoma, bladder cancer, head and neck cancer FDA granted accelerated approval to Tecentriq for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy

  • Durvalumab (Imfinzi) was approved in 2017 as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80.
  • In December 2017, nivolumab (Opdivo) received approval for adjuvant treatment of melanoma.
  • In August 2017, Novartis received approval for CAR-T therapy named Kymriah for children and young adult with B- cell lymphoblastic lymphoma.
  • Gilead Life Science completed the acquisition of Kite pharma Ltd. in October 2017, for around US$ 1.3 billion. Gilead’s CAR-T therapy Yescarta received FDA approval in October 2017 to treat non-Hodgkin lymphoma.
  • Celgene Corporation, in January 2018, announced acquisition of Juno Therapeutics, Inc. for US$ 9 billion. Through this acquisition, Celgene Corporation would gain access to novel CAR-T therapy, which is in pipeline of Juno Therapeutics.
  • Amgen received FDA approval in 2017, for Imlygic, which is an oncolytic virus to treat melanoma.
  • In March 2017, FDA approved the avelumab (Bavencio) in metastatic Merkel cell carcinoma which is rare disease, EMD serono and Pfizer Inc. jointly developed it.

Key players operating in the immuno-oncology drugs market include Amgen Inc., AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co, F. Hoffmann-La Roche AG, Johnson & Johnson,, Novartis International AG, Abbvie, Inc., Pfizer Inc., EMD Serono, Inc. and Gilead Lifescinces Inc.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.